Clicky

Delmar Pharmaceuticals Inc - Warrants [16/08/202(DMPWW)

Description: DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China; and Duke University to evaluate VAL-083 as a front-line treatment for newly diagnosed patients with GBM. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Vancouver, Canada.


Keywords: Medicine Cancer Clinical Medicine Solid Tumors Oncology Drug Development Ovarian Cancer Glioblastoma Blastoma Nose Targeted Therapy Brain Tumor Cancer Therapies Guangxi Stoma Glioblastoma Multiforme Anti Cancer Therapies Cancer Patients

Home Page:

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: June
Full Time Employees: 4
Back to stocks